Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Status:
RECRUITING
Trial end date:
2039-06-01
Target enrollment:
Participant gender:
Summary
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization.
The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.
Phase:
PHASE3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Cancer Trials Ireland Spanish Oncology Genito-Urinary Group UNICANCER